|
|
|
| Current Situation and Prospects of Therapeutic Antibody |
| GE Liang-peng1,2,3, DING Ning1, LAN Guo-cheng4, ZOU Xian-gang4, LIU Zuo-hua 1,2,3 |
1. Chongqing Academy of Animal Sciences, Chongqing 402460, China;
2. Key Laboratory of Pig Industry Sciences, Ministry of Agriculture, Chongqing 402460, China;
3. Chongqing Key Laboratory of Pig Industry Sciences, Chongqing 402460, China;
4. Cancer Research UK/Cambridge Research Institute, Cambridge CB20RE |
|
|
|
Abstract The paper reviewed the current situation and prospects of human therapeutic antibodies in the aspect of the progress of fully humanized antibody, the clinical research situation and future development of therapeutic antibody. Firstly,we compare the difference between fully humanized antibody and humanized antibody, and introduce the progress,advantage and disadvantage, and develop direction of fully humanized antibody produced by Phage Display technology and transgenic animal technology in detail. Then we also discuss several key technical problems of therapeutic antibodies in clinic research, including the current clinic research situation, therapeutic antibodies mechanism,the choice of target antigen, and challenge in antibodies production and application etc. Finally, we outlined the future trends for therapeutic antibody development in small therapeutic antibody, immunoconjugates, bispecific antibodies, Intracellular antibodies, Fc-modified antibody, antibody glycosylation and polyclonal antibody.
|
|
Received: 16 May 2013
Published: 25 September 2013
|
|
|
|
|
[1] Waldmann T A.Immunotherapy: past, present and future. Nat Med, 2003(9):269-277.
[2] Smith S L. Ten years of Orthoclone OKT3 (muromonab-CD3): a review. J Transpl Coord,1996(6): 109-119.
[3] Pendley C, Schantz A, Wagner C. Immunogenicity of therapeutic monoclonal antibodies. Curr Opin Mol Ther, 2003(5):172-179.
[4] Morrison S L, Johnson M J, Herzenberg L A, et al. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci USA, 1984,81:6851-6855.
[5] Jones P T, Dear P H, Foote J, et al. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature, 1986,321:522-525.
[6] Caldas C,Ceelho V,Kalil J,et a1. Flumanimdon ofthe anti-CDl8 antibody 6.7:an unexpected effect of a framework residue in binding to antigen. Mol Immunol, 2003,39:941-952.
[7] Winter G, Harris W J. Humanized Antibodies. Immunol Today,1993,14:243-246.
[8] Lonberg, N. Human antibodies from transgenic animals. Nat Biotechnol, 2005,23: 1117-1125.
[9] McCafferty J, Griffiths A D, Winter G, et al. Phage antibodies: filamentous phage displaying antibody variable domains. Nature,1990,348:552-554.
[10] Lu Z J, Deng S J, Huang D G, et al. Frontier of therapeutic antibody discovery: The challenges and how to face them. World J Biol Chem, 2012(3): 187-196.
[11] Lapenta C, Santini S M, Logozzi M, et al. Potent immune response against HIV21 and protection from virus challenge in hu2PBL2SCID mice immunized with inactivated virus2pulsed dendritic cells generated in the presence of IFN-alphaJ. J Exp Med, 2003,198:361-367.
[12] Johan R, John L, Barbara H, et al. Epitope mapping of antibodies using bacterial surface display. Nat Methods, 2008(5):1039-1045.
[13] van den Beucken T, Pieters H, Steukers M, et al. Affinity maturation of Fab antibody fragments by fluorescent activated cell sorting of yeast-displayed librariesJ. FEBS Lett, 2003,546:288-294.
[14] Hanes J, Schaffitzel C, Knappik A, et al. Picomolar affinity antibodies from a fully synthetic na g ve library selected and envolved by ribosome displayJ. Nat Biotechnol, 2000,18:1287-1292.
[15] Dufner P, Jermutus L, Minter R R. Harnessing phage and ribosome display for antibody optimisation. Trends Biotechnol, 2006, 24: 523-529.
[16] Glanville J, Zhai W, Berka J, et al. Precise determination of the diversity of a combinatorial antibody library gives insight into the human immunoglobulin repertoire. Proc Natl Acad Sci USA, 2009,106: 20216-20221.
[17] Prabakaran P, Chen W, Singarayan MG, et al. Expressed antibody repertoires in human cord blood cells: 454 sequencing and IMGT/HighV-QUEST analysis of germline gene usage, junctional diversity, and somatic mutations. Immunogenetics, 2012, 64: 337-350.
[18] Zhai W, Glanville J, Fuhrmann M, et al. Synthetic antibodies designed on natural sequence landscapes. J Mol Biol, 2011, 412: 55-71.
[19] Glanville J, Kuo T C, von Büdingen H C,et al. Naive antibody gene-segment fre-quencies are heritable and unaltered by chronic lymphocyte ablation. Proc Natl Acad Sci USA, 2011,108: 20066-20071.
[20] Nelson A L, Reichert J M.Development trends for therapeutic antibody fragments. Nat biotechnol, 2009,27:331-337.
[21] Brüggemann M, Caskey HM, Teale C,et al. A repertoire of monoclonal antibodies with human heavy chains from transgenic mice. Proc Natl Acad Sci U S A, 1989,86:6709-6713.
[22] Lonberg N, Taylor L D, Harding F A, et al.Antigen-specific human antibodies from mice comprising four distinct genetic modifications. Nature, 1994,368:856-859.
[23] Green L L, Hardy M C, Maynard-Currie C E, et al. Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs. Nat Genet, 1994(7):13-21.
[24] Kuroiwa Y, Kasinathan P, Sathiyaseelan1 T,et al.Antigen-specific human polyclonal antibodies from hyperimmunized cattle. Nat Biotechnol, 2009(27):173-181.
[25] Nicholson I C, Zou X, Popov A V, et al. Antibody repertoires of four-and five-feature translocus mice carrying human immunoglobulin heavy chain and kappa and lambda light chain yeast artificial chromosomes. J Immunol, 1999,163:6898-6906.
[26] Mendez M J, Green L L, Corvalan J R, et al.Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice. Nat Genet, 1997(15):146-156.
[27] Zhu L, Lavoir M, Albanese J,et al. Production of human monoclonal antibody in eggs of chimeric chickens. Nat Biotechnol, 2005(23):1159-1169.
[28] Mendicino M, Ramsoondar J, Phelps C, et al. Generation of antibody-and B cell-deficient pigs by targeted disruption of the J-region gene segment of the heavy chain locus. Transgenic Res, 2011(20):625-641.
[29] Nelson A L, Dhimolea E, Reichert J M. Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov, 2010(9):79-67-774.
[30] Chan A C, Carter P J. Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol, 2010(10):301-316.
[31] Scott A M, Wolchok J D, Old L J. Antibody therapy of cancer. Nat Rev Cancer, 2012(12):278-287.
[32] Holliger P, Hudson P J. Engineered antibody fragments and the rise of single domains. Nat Biotechnol, 2005,23:1126-1136.
[33] Abuchowski A, McCoy J R, Palczuk N C, et al. Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. J Biol Chem, 1977,252:3582-3586.
[34] Jenssens R, Dekker S, Hendriks R W et al. Generation of heavy-chain-only antibodies in mice. PNAS, 2006,103,41:15130-15135.
[35] Neuwelt E A, Barnett P A, Hellstrm I, et al. Delivery of melanoma-associated immunoglobulin monoclonal antibody and Fab fragments to normal brain utilizing osmotic blood-brain barrier disruption. Cancer Res, 1988,48:4725-4729.
[36] Fujimori K, Covell D G, Fletcher J E, et al. Modeling analysis of the global and microscopic distribution of immunoglobulin G, F(ab’)2, and Fab in tumors. Cancer Res, 1989,49:5656-5663.
[37] Stijlemans B, Conrath K, Cortez-Retamozo V, et al. Efficient Targeting of Conserved Cryptic Epitopes of Infectious Agents by Single Domain Antibodies. J Biol Chem, 2004,279:1256-1261.
[38] Wu A M, Senter P D. Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol, 2005,23:1137-1146.
[39] Hudson P J, Souriau C. Engineered antibodies. Nat Med, 2003(9):129-134.
[40] Rother R P, Rollins S A, Mojcik C F, et al. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nature Biotechnol, 2007,25:1256-1264.
[41] Carter P J. Potent antibody therapeutics by design. Nat Rev Immunol, 2006(6):343-357.
[42] Raju T S. Glycosylation variations with expression systems and their impact on biological activity of therapeutic immunoglobulins. Bioprocess International, 2003(1):44-53.
[43] Jefferis R. Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug Discov, 2009(8):226-234.
[44] Newcombe C, Newcombe A R. Antibody production: Polyclonal-derived biotherapeutics. J Chromatogr B Analyt Technol Biomed Life Sci, 2007,15:2-7. |
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
